Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice

Neurotoxicity Research

Volumn 22, Issue 1, 2012, Pages 33-42

  Bachurin, Sergey O ^a   Shelkovnikova, Tatyana A ^a,b   Ustyugov, Alexey A ^a,b   Peters, Owen ^b   Khritankova, Ina ^a   Afanasieva, Marina A ^a   Tarasova, Tatyana V ^a   Alentov, Igor I ^a   Buchman, Vladimir L ^b   Ninkina, Natalia N ^a,b  

^a INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

ALS; C Synuclein; Dimebolin; Latrepirdine; Neuroprotection; Proteinopathy; Transgenic mouse model

Indexed keywords

AMYLOID PROTEIN; DIMEBON; DRINKING WATER; GAMMA SYNUCLEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL ANIMAL; MALE; MOTOR PERFORMANCE; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEINOPATHY; ROTAROD TEST; SINGLE DRUG DOSE; SPINAL CORD NERVE CELL; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GAMMA-SYNUCLEIN; INDOLES; MALE; MICE; MICE, TRANSGENIC; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; ROTAROD PERFORMANCE TEST; SPINAL CORD;

ANIMALIA; MUS MUSCULUS;

EID: 84861456266     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-011-9299-y     Document Type: Article

References (40)

1. Allaman I, Bélanger M, Magistretti PJ (2011) Astrocyte-neuron metabolic relationships: For better and for worse. Trends Neurosci 34:76-87
2. Archer T, Kostrzewa RM, Beninger RJ, Palomo T (2011) Staging neurodegenerative disorders: Structural, regional, biomarker, and functional progressions. Neurotoxic Res 19:211-234
3. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sablin S, Zefirov N (2001) Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 939:425-435 (Pubitemid 32620096)
4. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO (2003) Mitochondria as a target for neurotoxins and neuroprotective agents. Ann NY Acad Sci 993:334-344 (Pubitemid 36808462)
5. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416:507-511 (Pubitemid 34288846)
6. Buchman VL, Adu J, Pinon LG, Ninkina NN, Davies AM (1998) Persyn, a member of the synuclein family, influences neurofilament network integrity. Nat Neurosci 1:101-103
7. Buchman VL, Luke C, Borthwick EB, Ninkina NN (2002) Organisation of the mouse Ruk locus and expression of isoforms in mouse tissues. Gene 295:13-17 (Pubitemid 35283811)
8. Caughey B, Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26:267-298 (Pubitemid 37064935)
9. Doody S, Gavrilova SI, Sano M et al (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study. Lancet 372:207-215 (Pubitemid 351978110)
10. Farina C, Aloisi F, Meinl E (2007) Astrocytes are active players in cerebral innate immunity. Trends Immunol 28:138-145 (Pubitemid 46283692)
11. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34:521-533 (Pubitemid 34628750)
12. Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T, Altar CA, Wronski R, Hutter-Paier B, Protter AA (2010) Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism. J Pharmacol Exp Ther 333:748-757
13. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140:918-934
14. Grigorev VV, Dranyi OA, Bachurin SO (2003) Comparative study of action mechanisms of dimebon and memantine on AMPA-and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 136:474-477 (Pubitemid 39137308)
15. Kieburtz K, McDermott MP, Voss TS et al (2010) A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol 67:154-160
16. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr (2002) Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature 418:291 (Pubitemid 34790672)
17. Lermontova NN, Redkozubov AE, Shevtsova EF, Serkova TP, Kireeva EG, Bachurin SO (2001) Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2?) channels. Bull Exp Biol Med 132:1079-1083 (Pubitemid 34295938)
18. Leurs R, Church MK, Taglialatela M (2002) H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 32:489-498 (Pubitemid 34429565)
19. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408 (Pubitemid 34164012)
20. Naga KK, Geddes JW (2011) Dimebon inhibits calcium-induced swelling of rat brain mitochondria but does not alter calcium retention or cytochrome C release. Neuromolecular Med 13:31-36
21. Ninkina N, Papachroni K, Robertson DC, Schmidt O, Delaney L, O'Neill F, Court F, Rosenthal A, Fleetwood-Walker SM, Davies AM, Buchman VL (2003) Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene. Mol Cell Biol 23:8233-8245 (Pubitemid 37377513)
22. Ninkina N, Peters O, Millership S, Salem H, van der Putten H, Buchman VL (2009) c-Synucleinopathy: Neurodegeneration associated with overexpression of the mouse protein. Hum Mol Genet 18:1779-1794
23. Nirogi R, Kandikere V, Mudigonda K, Komarneni P, Boggavarapu R (2009) Liquid chromatography-tandem mass spectrometry method for the quantification of dimebon in rat plasma and brain tissue. J Chromatogr B Anal Technol Biomed Life Sci 877:3563-3571
24. Okun I, Tkachenko SE, Khvat A, Mitkin O, Kazey V, Ivachtchenko AV (2010) From anti-allergic to anti-Alzheimer's: molecular pharmacology of Dimebon. Curr Alzheimer Res 7:97-112
25. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM (2005) A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128:2665-2674 (Pubitemid 41552950)
26. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, Papadimitriou A, Kalofoutis A, Buchman VL (2007) Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 101:749-756 (Pubitemid 46633311)
27. Pieper AA, Xie S, Capota E et al (2010) Discovery of a proneurogenic, neuroprotective chemical. Cell 142:39-51
28. Robertson DC, Schmidt O, Ninkina N, Jones PA, Sharkey J, Buchman VL (2004) Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gammasynuclein null mutant mice. J Neurochem 89:1126-1136 (Pubitemid 38715830)
29. Rowe DB, Le W, Smith RG, Appel SH (1998) Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. J Neurosci Res 53:551-558 (Pubitemid 28380796)
30. Rubinsztein DC (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443:780-786 (Pubitemid 44622682)
31. Shelkovnikova TA, Ustyugov AA, Millership S, Peters O, Anichtchik O, Spillantini MG, Buchman VL, Bachurin SO, Ninkina NN (2011) Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alphasynuclein in dopaminergic neurons of transgenic mice. Neurodegener Dis 8:430-437
32. Skovronsky DM, Lee VM, Trojanowski JQ (2006) Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 1:151-170
33. Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL, Westaway D, Fraser P, Hyslop PS, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S (2009) Acute dosing of latrepirdine (Dimebon), a possibleAlzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener 4:51
34. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A betadeposition in the human brain and its relevance for the development of AD. Neurology 58:1791-1800 (Pubitemid 34663580)
35. Uversky VN (2009) Intrinsic disorder in proteins associated with neurodegenerative diseases. Front Biosci 14:5188-5238
36. Wang J, Ferruzzi MG, Varghese M, Qian X, Cheng A, Xie M, Zhao W, Ho L, Pasinetti GM (2011) Preclinical study of dimebon on b-amyloid-mediated neuropathology in Alzheimer's disease. Mol Neurodegener 6:7
37. Webster SJ, Wilson CA, Lee CH, Mohler EG, Terry AV Jr, Buccafusco JJ (2011) The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys. Br J Pharmacol 164:970-978
38. Wu J, Li Q, Bezprozvanny I (2008) Evaluation of Dimebon in cellular model of Huntington's disease. Mol Neurodegener 3:15
39. Yamashita M, Nonaka T, Arai T, Kametani F, Buchman VL, Ninkina N, Bachurin SO, Akiyama H, Goedert M, Hasegawa M (2009) Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett 583:2419-2424
40. Zhang S, Hedskog L, Petersen CA, Winblad B, Ankarcrona A (2010) Dimebon (Latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis 21:389-402